IPHA
Innate Pharma
IPHA
IPHA
13 hedge funds and large institutions have $3.2M invested in Innate Pharma in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
13
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$364K | |
| 2 | +$77.4K | |
| 3 | +$18.9K | |
| 4 |
Barclays
London,
United Kingdom
|
+$11K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$3K |
Top Sellers
| 1 | -$839K | |
| 2 | -$498K | |
| 3 | -$364K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$242K |
| 5 |
Two Sigma Investments
New York
|
-$104K |